Post-transplant NASH Protocol to Assess the Development of Metabolic Co-morbidities and Disease Recurrence in Patients Transplanted for NASH Cirrhosis


About this study

The purpose of this study is to identify risk factors and potential predictors for NAFLD and NASH recurrence after liver transplantation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subject of at least 18 years of age at time of transplant;
  • Transplanted with a primary or secondary diagnosis of NASH defined as meeting one of the following criteria:
    • Confirmed NASH cirrhosis prior to transplantation;
    • Cryptogenic cirrhosis in the setting of features of the metabolic syndrome and no other discernible cause of liver disease other than probable NASH;
  • Patients with non-immune liver disease who were non-viremic at time of transplant who also had NASH as defined in a) and b).

Exclusion Criteria:

  • Subject under 18 years of age;
  • Other cause of liver disease;
  • HIV +.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kymberly Watt, M.D.

Closed-enrolling by invitation

What is this? (?)
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Kymberly Watt M.D.


More information


Publications are currently not available

Mayo Clinic Footer